Evidence map›Paper›PMID 33898628›Full record

ArticleMolecular therapy. Methods & clinical development2021

Robust hepatitis B vaccine-reactive T cell responses in failed humoral immunity.

Gounwa Awad, Toralf Roch, Ulrik Stervbo, Sviatlana Kaliszczyk, Anna Stittrich, Jan Hörstrup, Ocan Cinkilic, Heiner Appel, Larysa Natrus, Ludmila Gayova and 5 more

Open access · goldAbstract read
In one paragraph

Article in Molecular therapy. Methods & clinical development, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 2 countries.

Gounwa AwadUniversity Hospital Marien Hospital Herne, Ruhr-University of Bochum, Bochum, Germany.
Toralf RochUniversity Hospital Marien Hospital Herne, Ruhr-University of Bochum, Bochum, Germany.
Ulrik StervboUniversity Hospital Marien Hospital Herne, Ruhr-University of Bochum, Bochum, Germany.
Sviatlana KaliszczykUniversity Hospital Marien Hospital Herne, Ruhr-University of Bochum, Bochum, Germany.
Anna StittrichBIH Center for Regenerative Therapies, Charité - University Medicine Berlin, corporate member of Free University of Berlin, Humboldt University of Berlin, and Berlin Institute of Health, Berlin, Germany.
Jan HörstrupKfH Kuratorium für Dialyse und Nierentransplantation e.V., Berlin, Germany.
Ocan CinkilicDialyse Schwerte, Schwerte, Germany.
Heiner AppelDialysezentrum Hamm, Hamm, Germany.
Larysa NatrusBogomolets National Medical University, Kyiv, Ukraine.
Ludmila GayovaBogomolets National Medical University, Kyiv, Ukraine.
Felix SeibertUniversity Hospital Marien Hospital Herne, Ruhr-University of Bochum, Bochum, Germany.
Frederic BauerUniversity Hospital Marien Hospital Herne, Ruhr-University of Bochum, Bochum, Germany.
Timm WesthoffUniversity Hospital Marien Hospital Herne, Ruhr-University of Bochum, Bochum, Germany.
Mikalai NienenBIH Center for Regenerative Therapies, Charité - University Medicine Berlin, corporate member of Free University of Berlin, Humboldt University of Berlin, and Berlin Institute of Health, Berlin, Germany.
Nina BabelUniversity Hospital Marien Hospital Herne, Ruhr-University of Bochum, Bochum, Germany.
Universitätsklinik Marien Hospital Herne · DEBogomolets National Medical University · UAPHV Dialysezentrum · DEHumboldt-Universität zu Berlin · DEKfH Kuratorium für Dialyse und Nierentransplantation · DEVivantes Klinikum · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

While virus-specific antibodies are broadly recognized as correlates of protection, virus-specific T cells are important for direct clearance of infected cells. Failure to generate hepatitis B virus (HBV)-specific antibodies is well-known in patients with end-stage renal disease. However, whether and to what extent HBV-specific cellular immunity is altered in this population and how it influences humoral immunity is not clear. To address it, we analyzed HBV-reactive T cells and antibodies in hemodialysis patients post vaccination. 29 hemodialysis patients and 10 healthy controls were enrolled in a cross-sectional study. Using multiparameter flow cytometry, HBV-reactive T cells were analyzed and functionally dissected based on granzyme B, interferon-γ (IFN-γ), tumor necrosis factor alpha (TNF-α), interleukin-2 (IL-2), and IL-4 expression. Importantly, HBV-reactive CD4

Indexed as

failed Hepatitis B vaccinationpolyfunctional T cellsT cell memory

Identifiers

PMID33898628
PMCPMC8050104
OpenAlexW3136305853

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.